You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFlurbiprofen
Accession NumberDB00712  (APRD00753)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionFlurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.
Structure
Thumb
Synonyms
(+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid
2-(2-Fluorobiphenyl-4-yl)propanoic acid
2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid
3-Fluoro-4-phenylhydratropic acid
Ansaid
FLP
Flurbiprofen
Flurbiprofene
Flurbiprofeno
Flurbiprofenum
S-flurbiprofen
External Identifiers
  • BTS 18 322
  • FP 70
  • FP 83
  • U 27182
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ansaid Tablets 100 mgtablet100 mgoralPfizer Canada Inc1985-12-312013-07-25Canada
Ansaid Tablets 50 mgtablet50 mgoralPfizer Canada Inc1985-12-312013-07-25Canada
Flurbiprofen Sodiumsolution/ drops.3 mg/mLophthalmicRebel Distributors Corp1997-05-29Not applicableUs
Flurbiprofen Sodiumsolution/ drops.3 mg/mLophthalmicPacific Pharma, Inc.1997-05-29Not applicableUs
Flurbiprofen-100 Tab 100mgtablet100 mgoralPro Doc Limitee1992-12-312009-07-23Canada
Flurbiprofen-50 Tab 50mgtablet50 mgoralPro Doc Limitee1992-12-312009-07-23Canada
Frobentablet100 mgoralAbbott Laboratories, Limited1996-12-162008-06-06Canada
Frobentablet50 mgoralAbbott Laboratories, Limited1997-02-062008-06-06Canada
Froben SRcapsule (sustained-release)200 mgoralAbbott Laboratories, Limited1997-01-282008-06-06Canada
Froben Tab 100mgtablet100 mgoralOrganon Canada Ltd Ltee1986-12-311996-09-10Canada
Froben Tab 50mgtablet50 mgoralOrganon Canada Ltd Ltee1986-12-311996-09-10Canada
Froben-SR Cap 200mgcapsule (sustained-release)200 mgoralOrganon Canada Ltd Ltee1990-12-311996-09-10Canada
Novo-flurprofen SRcapsule (sustained-release)200 mgoralNovopharm LimitedNot applicableNot applicableCanada
Nu-flurbiprofen Tab 100mgtablet100 mgoralNu Pharm Inc1993-12-312012-09-04Canada
Nu-flurbiprofen Tab 50mgtablet50 mgoralNu Pharm Inc1993-12-312012-09-04Canada
Ocufensolution/ drops.3 mg/mLophthalmicAllergan, Inc.1987-01-01Not applicableUs
Ocufen Oph Soln 0.03%liquid0.03 %ophthalmicAllergan Inc1988-12-312011-08-04Canada
Ratio-flurbiprofen Tablets 100mgtablet100 mgoralRatiopharm Inc Division Of Teva Canada Limited1991-12-312006-08-04Canada
Ratio-flurbiprofen Tablets 50mgtablet50 mgoralRatiopharm Inc Division Of Teva Canada Limited1991-12-312006-08-04Canada
Teva-flurbiprofentablet50 mgoralTeva Canada Limited1994-12-31Not applicableCanada
Teva-flurbiprofentablet100 mgoralTeva Canada Limited1994-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-flurbiprofen Fc Tablets 100mgtablet100 mgoralApotex Inc1991-12-31Not applicableCanada
Apo-flurbiprofen Fc Tablets 50mgtablet50 mgoralApotex Inc1991-12-31Not applicableCanada
Flurbiprofentablet, film coated100 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-07Not applicableUs
Flurbiprofentablet, film coated100 mg/1oralTeva Pharmaceuticals USA Inc1995-06-02Not applicableUs
Flurbiprofentablet, film coated100 mg/1oralPhysicians Total Care, Inc.1997-02-24Not applicableUs
Flurbiprofentablet, film coated50 mg/1oralMylan Pharmaceuticals Inc.1994-06-20Not applicableUs
Flurbiprofentablet, film coated100 mg/1oralPd Rx Pharmaceuticals, Inc.2011-05-20Not applicableUs
Flurbiprofentablet, film coated100 mg/1oralMylan Pharmaceuticals Inc.1994-06-20Not applicableUs
Flurbiprofentablet, film coated100 mg/1oralA S Medication Solutions1995-06-02Not applicableUs
Flurbiprofentablet, film coated100 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-05-20Not applicableUs
Flurbiprofentablet, film coated100 mg/1oralbryant ranch prepack1995-06-02Not applicableUs
Flurbiprofentablet, film coated100 mg/1oralSTAT Rx USA LLC1994-06-20Not applicableUs
Flurbiprofen Sodiumsolution/ drops.242 mg/mLophthalmicRebel Distributors Corp1995-01-04Not applicableUs
Flurbiprofen Sodiumsolution/ drops.3 mg/mLophthalmicBausch & Lomb Incorporated1995-01-04Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Antiphlamine Pain Relievingpatch33 mg/51topicalHanul Trading Co., Ltd.2015-09-01Not applicableUs
International Brands
NameCompany
Acustop CataplasmaSang-A
AdofeedLead Chemical
AnsaidPfizer
AntadysTheramex
CebutidAlmirall
FlurofenAbbott Laboratories Ltd.
OcuflurAllergan
StaybanTokuhon
StrefenReckitt Benckiser
StrepfenReckitt Benckiser
StrepsilsReckitt Benckiser
Strepsils IntensiveReckitt Benckiser
TransActReckitt Benckiser
UrbifenGeneral Pharma
ZepolasMikasa Seiyaku
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Flurbiprofen Sodium
Thumb
  • InChI Key: AUAGTGKMTMVIKN-UHFFFAOYNA-M
  • Monoisotopic Mass: 266.071902508
  • Average Mass: 266.2428
DBSALT000544
Categories
UNII5GRO578KLP
CAS number5104-49-4
WeightAverage: 244.2609
Monoisotopic: 244.089957865
Chemical FormulaC15H13FO2
InChI KeyInChIKey=SYTBZMRGLBWNTM-UHFFFAOYSA-N
InChI
InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
IUPAC Name
2-(3-fluoro-4-phenylphenyl)propanoic acid
SMILES
CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBiphenyls and derivatives
Direct ParentBiphenyls and derivatives
Alternative Parents
Substituents
  • Biphenyl
  • 2-phenylpropanoic-acid
  • Phenylacetate
  • Monoterpenoid
  • Monocyclic monoterpenoid
  • Aromatic monoterpenoid
  • P-cymene
  • Halobenzene
  • Fluorobenzene
  • Aryl halide
  • Aryl fluoride
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFlurbiprofen tablets are indicated for the acute or long-term symptomatic treatment of rheumatoid arthritis, osteorarthritis and anklosing spondylitis. It may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e.g. bursitis, tendonitis, soft tissue trauma). Topical ophthalmic formulations may be used pre-operatively to prevent intraoperative miosis.
PharmacodynamicsFlurbiprofen, a nonsteroidal anti-inflammatory agent (NSAIA) of the propionic acid class, is structually and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen, and has similar pharmacological actions to other prototypica NSAIAs. Flurbiprofen exhibits antiinflammatory, analgesic, and antipyretic activities. The commercially available flurbiprofen is a racemic mixture of (+)S- and (-) R-enantiomers. The S-enantiomer appears to possess most of the anti-inflammatory, while both enantiomers may possess analgesic activity.
Mechanism of actionSimilar to other NSAIAs, the anti-inflammatory effect of flurbiprofen occurs via reversible inhibition of cyclooxygenase (COX), the enzyme responsible for the conversion of arachidonic acid to prostaglandin G2 (PGG2) and PGG2 to prostaglandin H2 (PGH2) in the prostaglandin synthesis pathway. This effectively decreases the concentration of prostaglandins involved in inflammation, pain, swelling and fever. Flurbiprofen is a non-selective COX inhibitor and inhibits the activity of both COX-1 and -2. It is also one of the most potent NSAIAs in terms of prostaglandin inhibitory activity.
Related Articles
AbsorptionFluribiprofen is rapidly and almost completely absorbed following oral administration. Peak plasma concentrations are reached 0.5 - 4 hours after oral administration.
Volume of distribution
  • 14 L [Normal Healthy Adults]
  • 12 L [Geriatric Arthritis Patients]
  • 10 L [End Stage Renal Disease Patients]
  • 14 L [Alcoholic Cirrhosis Patients]
  • 0.12 L/kg
Protein binding> 99% bound, primarily to albumin. Binds to a different primary binding site on albumin than anticoagulants, sulfonamides and phenytoin.
Metabolism

Hepatic. Cytochrome P450 2C9 plays an important role in the metabolism of flurbiprofen to its major metabolite, 4’-hydroxy-flurbiprofen. The 4’-hydroxy-flurbiprofen metabolite showed little anti-inflammatory activity in animal models of inflammation.

SubstrateEnzymesProduct
Flurbiprofen
4'-HydroxyflurbiprofenDetails
Flurbiprofen
Flurbiprofen glucuronideDetails
Route of eliminationFlurbiprofen is poorly excreted into human milk. Following dosing with flurbiprofen, less than 3% of flurbiprofen is excreted unchanged in the urine, with about 70% of the dose eliminated in the urine as parent drug and metabolites. Renal elimination is a significant pathway of elimination of flurbiprofen metabolites.
Half lifeR-flurbiprofen, 4.7 hours; S-flurbiprofen, 5.7 hours
ClearanceNot Available
ToxicityLD50=10 mg/kg (orally in dogs).

Selective COX-2 inhibitors have been associated with increased risk of serious cardiovascular events (e.g. myocardial infarction, stroke) in some patients. Current data is insufficient to assess the cardiovascular risk of flurbiprofen. Flurbiprofen may increase blood pressure and/or cause fluid retention and edema. Use caution in patients with fluid retention or heart failure. Risk of GI toxicity including bleeding, ulceration and perforation. Risk of direct renal injury, including renal papillary necrosis. Anaphylactoid and serious skin reactions (e.g. exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) may occur. Common adverse events include abdominal pain, constipation, diarrhea, dyspepsia, flatulence, GI bleeding, GI perforation, nausea, peptic ulcer, vomiting, renal function abnormalities, anemia, dizziness, edema, liver function test abnormalities, headache, prolonged bleeding time, pruritus, rash, tinnitus. Although rarely documented in the case of flurbiprofen, oral propionic acid derivatives have been associated with a relatively high frequency of allergic reactions.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Flurbiprofen Action PathwayDrug actionSMP00697
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9824
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.76
P-glycoprotein inhibitor INon-inhibitor0.9061
P-glycoprotein inhibitor IINon-inhibitor0.9739
Renal organic cation transporterNon-inhibitor0.912
CYP450 2C9 substrateNon-substrate0.7247
CYP450 2D6 substrateNon-substrate0.9249
CYP450 3A4 substrateNon-substrate0.7205
CYP450 1A2 substrateInhibitor0.8663
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9546
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9674
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8752
Ames testNon AMES toxic0.9659
CarcinogenicityNon-carcinogens0.5554
BiodegradationNot ready biodegradable0.9861
Rat acute toxicity3.1121 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9849
hERG inhibition (predictor II)Non-inhibitor0.9116
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Caraco pharmaceutical laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Pliva inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Theragen inc
  • Bausch and lomb inc
  • Allergan pharmaceutical
Packagers
Dosage forms
FormRouteStrength
Patchtopical33 mg/51
Tabletoral100 mg
Tabletoral50 mg
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral50 mg/1
Solution/ dropsophthalmic.242 mg/mL
Capsule (sustained-release)oral200 mg
Solution/ dropsophthalmic.3 mg/mL
Liquidophthalmic0.03 %
Prices
Unit descriptionCostUnit
Ocufen 0.03% Solution 2.5ml Bottle22.7USD bottle
Flurbiprofen powder20.9USD g
Flurbiprofen Sodium 0.03% Solution 2.5ml Bottle15.99USD bottle
Ocufen 0.03% eye drops10.63USD ml
Flurbiprofen 0.03% eye drop4.37USD ml
Ansaid 100 mg tablet2.1USD tablet
Flurbiprofen 100 mg tablet1.08USD tablet
Flurbiprofen 50 mg tablet0.8USD tablet
Ansaid 50 mg Tablet0.58USD tablet
Apo-Flurbiprofen 100 mg Tablet0.37USD tablet
Novo-Flurprofen 100 mg Tablet0.37USD tablet
Nu-Flurbiprofen 100 mg Tablet0.37USD tablet
Apo-Flurbiprofen 50 mg Tablet0.27USD tablet
Novo-Flurprofen 50 mg Tablet0.27USD tablet
Nu-Flurbiprofen 50 mg Tablet0.27USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point110-111 °CAdams, S.S., Bernard, J., Nicholson, J.S. and Blancafort, A.R.; U.S. Patent 3,755,427; Aug. 28, 1973; assigned to The Boots Company Ltd.
water solubility8 mg/L (at 22 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.16HANSCH,C ET AL. (1995)
logS-4.49ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0249 mg/mLALOGPS
logP3.57ALOGPS
logP3.94ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)4.42ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity67.29 m3·mol-1ChemAxon
Polarizability25.23 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (126 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis Reference

Yutaka Mizushima, Hiroyuki Okamoto, Shigetoshi Sugio, Kazumasa Yokoyama, Tadakazu Suyama, Masao Tohno, Makoto Okumura, Yoshiaki Konishi, Kiyonoshin Ichikawa, Katsuhiro Uchida, “Flurbiprofen derivative ophthalmic preparation.” U.S. Patent US5171566, issued January, 1984.

US5171566
General References
  1. Geerts H: Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease. IDrugs. 2007 Feb;10(2):121-33. [PubMed:17285465 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Calapai G, Imbesi S, Cafeo V, Ventura Spagnolo E, Minciullo PL, Caputi AP, Gangemi S, Milone L: Fatal hypersensitivity reaction to an oral spray of flurbiprofen: a case report. J Clin Pharm Ther. 2013 Aug;38(4):337-8. doi: 10.1111/jcpt.12073. Epub 2013 May 13. [PubMed:23668805 ]
  4. Mironov GG, Logie J, Okhonin V, Renaud JB, Mayer PM, Berezovski MV: Comparative study of three methods for affinity measurements: capillary electrophoresis coupled with UV detection and mass spectrometry, and direct infusion mass spectrometry. J Am Soc Mass Spectrom. 2012 Jul;23(7):1232-40. doi: 10.1007/s13361-012-0386-y. Epub 2012 Apr 28. [PubMed:22544663 ]
External Links
ATC CodesM02AA19R02AX01M01AE09S01BC04
AHFS Codes
  • 28:08.04.92
  • 52:08.20
PDB EntriesNot Available
FDA labelDownload (234 KB)
MSDSDownload (75 KB)
Interactions
Drug Interactions
Drug
AbciximabFlurbiprofen may increase the anticoagulant activities of Abciximab.
AbirateroneThe metabolism of Flurbiprofen can be decreased when combined with Abiraterone.
AcebutololFlurbiprofen may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Aceclofenac.
AcenocoumarolFlurbiprofen may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Flurbiprofen.
Alendronic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Alendronic acid.
AliskirenFlurbiprofen may decrease the antihypertensive activities of Aliskiren.
AlprenololFlurbiprofen may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Flurbiprofen.
AmikacinFlurbiprofen may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideFlurbiprofen may decrease the antihypertensive activities of Amiloride.
AmiodaroneThe metabolism of Flurbiprofen can be decreased when combined with Amiodarone.
AncrodFlurbiprofen may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Antipyrine.
Antithrombin III humanFlurbiprofen may increase the anticoagulant activities of Antithrombin III human.
ApixabanFlurbiprofen may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Apremilast.
AprepitantThe metabolism of Flurbiprofen can be increased when combined with Aprepitant.
ArdeparinFlurbiprofen may increase the anticoagulant activities of Ardeparin.
ArgatrobanFlurbiprofen may increase the anticoagulant activities of Argatroban.
ArotinololFlurbiprofen may decrease the antihypertensive activities of Arotinolol.
AtenololFlurbiprofen may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Flurbiprofen.
BalsalazideFlurbiprofen may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Flurbiprofen.
BecaplerminFlurbiprofen may increase the anticoagulant activities of Becaplermin.
BefunololFlurbiprofen may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Flurbiprofen.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Flurbiprofen.
BenoxaprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Benoxaprofen.
BetaxololFlurbiprofen may decrease the antihypertensive activities of Betaxolol.
BevantololFlurbiprofen may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Flurbiprofen.
BisoprololFlurbiprofen may decrease the antihypertensive activities of Bisoprolol.
BivalirudinFlurbiprofen may increase the anticoagulant activities of Bivalirudin.
BopindololFlurbiprofen may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Bromfenac.
BufuralolFlurbiprofen may decrease the antihypertensive activities of Bufuralol.
BumetanideFlurbiprofen may decrease the diuretic activities of Bumetanide.
BupranololFlurbiprofen may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Flurbiprofen.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Flurbiprofen.
CapecitabineThe metabolism of Flurbiprofen can be decreased when combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Flurbiprofen.
CarbamazepineThe metabolism of Flurbiprofen can be increased when combined with Carbamazepine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Flurbiprofen.
CarprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Carprofen.
CarteololFlurbiprofen may decrease the antihypertensive activities of Carteolol.
CarvedilolFlurbiprofen may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Flurbiprofen.
CeliprololFlurbiprofen may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Flurbiprofen can be increased when it is combined with Ceritinib.
CertoparinFlurbiprofen may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Flurbiprofen.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Flurbiprofen.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Flurbiprofen.
CholecalciferolThe metabolism of Flurbiprofen can be decreased when combined with Cholecalciferol.
CholestyramineCholestyramine can cause a decrease in the absorption of Flurbiprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Flurbiprofen.
Citric AcidFlurbiprofen may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Flurbiprofen.
ClotrimazoleThe metabolism of Flurbiprofen can be decreased when combined with Clotrimazole.
ColesevelamColesevelam can cause a decrease in the absorption of Flurbiprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Flurbiprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineFlurbiprofen may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Flurbiprofen can be decreased when combined with Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with D-Limonene.
Dabigatran etexilateFlurbiprofen may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Flurbiprofen can be decreased when it is combined with Dabrafenib.
DalteparinFlurbiprofen may increase the anticoagulant activities of Dalteparin.
DanaparoidFlurbiprofen may increase the anticoagulant activities of Danaparoid.
DaunorubicinFlurbiprofen may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Deferasirox.
DelavirdineThe metabolism of Flurbiprofen can be decreased when combined with Delavirdine.
DesirudinFlurbiprofen may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Flurbiprofen.
DextranFlurbiprofen may increase the anticoagulant activities of Dextran.
Dextran 40Flurbiprofen may increase the anticoagulant activities of Dextran 40.
Dextran 70Flurbiprofen may increase the anticoagulant activities of Dextran 70.
Dextran 75Flurbiprofen may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Flurbiprofen.
DicoumarolFlurbiprofen may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Diflunisal.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Flurbiprofen.
DihydrostreptomycinFlurbiprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Flurbiprofen.
DoxorubicinFlurbiprofen may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneFlurbiprofen may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Droxicam.
Edetic AcidFlurbiprofen may increase the anticoagulant activities of Edetic Acid.
EdoxabanFlurbiprofen may increase the anticoagulant activities of Edoxaban.
EfavirenzThe metabolism of Flurbiprofen can be decreased when combined with Efavirenz.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Flurbiprofen.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Flurbiprofen.
EnoxaparinFlurbiprofen may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Epirizole.
EpirubicinFlurbiprofen may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneFlurbiprofen may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Flurbiprofen.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Flurbiprofen.
EsmololFlurbiprofen may decrease the antihypertensive activities of Esmolol.
Etacrynic acidFlurbiprofen may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Flurbiprofen.
Ethyl biscoumacetateFlurbiprofen may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Etoricoxib.
EtravirineThe metabolism of Flurbiprofen can be decreased when combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Flurbiprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Flurbiprofen.
FloxuridineThe metabolism of Flurbiprofen can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Flurbiprofen can be decreased when combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Flunixin.
FluorouracilThe metabolism of Flurbiprofen can be decreased when combined with Fluorouracil.
FluvastatinThe metabolism of Flurbiprofen can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Flurbiprofen can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Flurbiprofen.
Fondaparinux sodiumFlurbiprofen may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Flurbiprofen.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Flurbiprofen.
FosphenytoinThe metabolism of Flurbiprofen can be increased when combined with Fosphenytoin.
FramycetinFlurbiprofen may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideFlurbiprofen may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Flurbiprofen.
GemfibrozilThe metabolism of Flurbiprofen can be decreased when combined with Gemfibrozil.
GentamicinFlurbiprofen may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Haloperidol.
HeparinFlurbiprofen may increase the anticoagulant activities of Heparin.
HirulogFlurbiprofen may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Flurbiprofen is combined with HMPL-004.
HydralazineFlurbiprofen may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Flurbiprofen.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Flurbiprofen.
Hygromycin BFlurbiprofen may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Icatibant.
IdarubicinFlurbiprofen may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Flurbiprofen.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Flurbiprofen.
IndenololFlurbiprofen may decrease the antihypertensive activities of Indenolol.
IndinavirThe metabolism of Flurbiprofen can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Flurbiprofen.
IndoprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Flurbiprofen.
IsoxicamThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Isoxicam.
KanamycinFlurbiprofen may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Kebuzone.
KetoconazoleThe metabolism of Flurbiprofen can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Flurbiprofen.
LabetalolFlurbiprofen may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Leflunomide.
LepirudinFlurbiprofen may increase the anticoagulant activities of Lepirudin.
LevobunololFlurbiprofen may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Flurbiprofen.
LithiumThe serum concentration of Lithium can be increased when it is combined with Flurbiprofen.
LornoxicamThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Flurbiprofen.
LovastatinThe metabolism of Flurbiprofen can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Flurbiprofen.
LumacaftorThe serum concentration of Flurbiprofen can be decreased when it is combined with Lumacaftor.
LumiracoxibThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Flurbiprofen.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Meloxicam.
MesalazineFlurbiprofen may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Flurbiprofen.
MetamizoleThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Flurbiprofen.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Flurbiprofen.
MetipranololFlurbiprofen may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Flurbiprofen.
MetoprololFlurbiprofen may decrease the antihypertensive activities of Metoprolol.
MetrizamideFlurbiprofen may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MifepristoneThe serum concentration of Flurbiprofen can be increased when it is combined with Mifepristone.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Flurbiprofen.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Flurbiprofen.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Flurbiprofen.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flurbiprofen.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Flurbiprofen.
NadololFlurbiprofen may decrease the antihypertensive activities of Nadolol.
NadroparinFlurbiprofen may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Flurbiprofen is combined with NCX 4016.
NeomycinFlurbiprofen may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Nepafenac.
NetilmicinFlurbiprofen may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NicardipineThe metabolism of Flurbiprofen can be decreased when combined with Nicardipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Flurbiprofen.
OlopatadineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Olopatadine.
OlsalazineFlurbiprofen may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Flurbiprofen.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Flurbiprofen.
OmeprazoleThe metabolism of Flurbiprofen can be decreased when combined with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Orgotein.
OtamixabanFlurbiprofen may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Oxaprozin.
OxprenololFlurbiprofen may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Parecoxib.
ParomomycinFlurbiprofen may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololFlurbiprofen may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateFlurbiprofen may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Flurbiprofen.
PhenindioneFlurbiprofen may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Flurbiprofen can be increased when combined with Phenobarbital.
PhenprocoumonFlurbiprofen may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Phenylbutazone.
PhenytoinThe metabolism of Flurbiprofen can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flurbiprofen.
PindololFlurbiprofen may decrease the antihypertensive activities of Pindolol.
PiretanideFlurbiprofen may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flurbiprofen.
PlicamycinFlurbiprofen may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Flurbiprofen.
PractololFlurbiprofen may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Flurbiprofen.
PrimidoneThe metabolism of Flurbiprofen can be increased when combined with Primidone.
ProbenecidThe serum concentration of Flurbiprofen can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Propacetamol.
PropranololFlurbiprofen may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Flurbiprofen.
Protein CFlurbiprofen may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeFlurbiprofen may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Flurbiprofen is combined with PTC299.
PuromycinFlurbiprofen may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PyrimethamineThe metabolism of Flurbiprofen can be decreased when combined with Pyrimethamine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Flurbiprofen.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Flurbiprofen.
QuinineThe metabolism of Flurbiprofen can be decreased when combined with Quinine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Flurbiprofen.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Flurbiprofen.
ResveratrolThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Resveratrol.
ReviparinFlurbiprofen may increase the anticoagulant activities of Reviparin.
RibostamycinFlurbiprofen may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifampicinThe metabolism of Flurbiprofen can be increased when combined with Rifampicin.
RifapentineThe metabolism of Flurbiprofen can be increased when combined with Rifapentine.
RisedronateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Risedronate.
RivaroxabanFlurbiprofen may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Flurbiprofen.
SalicylamideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Flurbiprofen.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Flurbiprofen.
SecobarbitalThe metabolism of Flurbiprofen can be increased when combined with Secobarbital.
SeratrodastThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Seratrodast.
SildenafilThe metabolism of Flurbiprofen can be decreased when combined with Sildenafil.
SorafenibThe metabolism of Flurbiprofen can be decreased when combined with Sorafenib.
SotalolFlurbiprofen may decrease the antihypertensive activities of Sotalol.
SpectinomycinFlurbiprofen may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Flurbiprofen.
SpironolactoneFlurbiprofen may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Flurbiprofen is combined with SRT501.
StreptomycinFlurbiprofen may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinFlurbiprofen may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfadiazineThe metabolism of Flurbiprofen can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Flurbiprofen can be decreased when combined with Sulfamethoxazole.
SulfasalazineFlurbiprofen may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Flurbiprofen.
SulfisoxazoleThe metabolism of Flurbiprofen can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Flurbiprofen.
SulodexideFlurbiprofen may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Suprofen.
TacrolimusFlurbiprofen may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Flurbiprofen.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Flurbiprofen.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Flurbiprofen.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Flurbiprofen.
TenofovirThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Flurbiprofen.
TepoxalinThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tiaprofenic acid.
TicagrelorThe metabolism of Flurbiprofen can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Flurbiprofen can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tiludronate.
TimololFlurbiprofen may decrease the antihypertensive activities of Timolol.
TobramycinFlurbiprofen may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TolbutamideThe metabolism of Flurbiprofen can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Flurbiprofen.
TorasemideFlurbiprofen may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Flurbiprofen.
TranilastThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Flurbiprofen.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Flurbiprofen.
TriamtereneFlurbiprofen may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Flurbiprofen.
TrimethoprimThe metabolism of Flurbiprofen can be decreased when combined with Trimethoprim.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Flurbiprofen.
Valproic AcidThe metabolism of Flurbiprofen can be decreased when combined with Valproic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Flurbiprofen.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Flurbiprofen.
VoriconazoleThe metabolism of Flurbiprofen can be decreased when combined with Voriconazole.
WarfarinFlurbiprofen may increase the anticoagulant activities of Warfarin.
XimelagatranFlurbiprofen may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Flurbiprofen can be decreased when combined with Zafirlukast.
ZaltoprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Zileuton.
Zoledronic acidThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Zomepirac.
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce gastric irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Rieke CJ, Mulichak AM, Garavito RM, Smith WL: The role of arginine 120 of human prostaglandin endoperoxide H synthase-2 in the interaction with fatty acid substrates and inhibitors. J Biol Chem. 1999 Jun 11;274(24):17109-14. [PubMed:10358065 ]
  2. Hewett SJ, Uliasz TF, Vidwans AS, Hewett JA: Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther. 2000 May;293(2):417-25. [PubMed:10773011 ]
  3. Kurahashi K, Shirahase H, Nakamura S, Tarumi T, Koshino Y, Wang AM, Nishihashi T, Shimizu Y: Nicotine-induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive oxygen species and COX-1 metabolites. J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S21-5. [PubMed:11811354 ]
  4. Klegeris A, McGeer PL: Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging. 2002 Sep-Oct;23(5):787-94. [PubMed:12392782 ]
  5. Droge MJ, van Sorge AA, van Haeringen NJ, Quax WJ, Zaagsma J: Alternative splicing of cyclooxygenase-1 mRNA in the human iris. Ophthalmic Res. 2003 May-Jun;35(3):160-3. [PubMed:12711844 ]
  6. Basselin M, Villacreses NE, Lee HJ, Bell JM, Rapoport SI: Flurbiprofen, a cyclooxygenase inhibitor, reduces the brain arachidonic acid signal in response to the cholinergic muscarinic agonist, arecoline, in awake rats. Neurochem Res. 2007 Nov;32(11):1857-67. Epub 2007 Jun 12. [PubMed:17562170 ]
  7. Nivsarkar M, Banerjee A, Padh H: Cyclooxygenase inhibitors: a novel direction for Alzheimer's management. Pharmacol Rep. 2008 Sep-Oct;60(5):692-8. [PubMed:19066416 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Bayly CI, Black WC, Leger S, Ouimet N, Ouellet M, Percival MD: Structure-based design of COX-2 selectivity into flurbiprofen. Bioorg Med Chem Lett. 1999 Feb 8;9(3):307-12. [PubMed:10091674 ]
  2. van Haeringen NJ, van Sorge AA, Carballosa Core-Bodelier VM: Constitutive cyclooxygenase-1 and induced cyclooxygenase-2 in isolated human iris inhibited by S(+) flurbiprofen. J Ocul Pharmacol Ther. 2000 Aug;16(4):353-61. [PubMed:10977131 ]
  3. Smith T, McCracken J, Shin YK, DeWitt D: Arachidonic acid and nonsteroidal anti-inflammatory drugs induce conformational changes in the human prostaglandin endoperoxide H2 synthase-2 (cyclooxygenase-2). J Biol Chem. 2000 Dec 22;275(51):40407-15. [PubMed:11006278 ]
  4. Hinz B, Brune K, Rau T, Pahl A: Flurbiprofen enantiomers inhibit inducible nitric oxide synthase expression in RAW 264.7 macrophages. Pharm Res. 2001 Feb;18(2):151-6. [PubMed:11405284 ]
  5. Hewett SJ, Uliasz TF, Vidwans AS, Hewett JA: Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther. 2000 May;293(2):417-25. [PubMed:10773011 ]
  6. Basselin M, Villacreses NE, Lee HJ, Bell JM, Rapoport SI: Flurbiprofen, a cyclooxygenase inhibitor, reduces the brain arachidonic acid signal in response to the cholinergic muscarinic agonist, arecoline, in awake rats. Neurochem Res. 2007 Nov;32(11):1857-67. Epub 2007 Jun 12. [PubMed:17562170 ]
  7. Nivsarkar M, Banerjee A, Padh H: Cyclooxygenase inhibitors: a novel direction for Alzheimer's management. Pharmacol Rep. 2008 Sep-Oct;60(5):692-8. [PubMed:19066416 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Mo SL, Zhou ZW, Yang LP, Wei MQ, Zhou SF: New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126. [PubMed:20167001 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M: Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):368-74. [PubMed:11259318 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A3
Uniprot ID:
P35503
Molecular Weight:
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as estriol, 4-hydroxyestrone and 2-hydroxyestriol) and xenobiotics (such as 4-methylumbelliferone, 1-naphthol, 4-nitrophenol, 2-aminophenol, 4-hydroxybiphenyl and menthol). It is capable of 6 alpha-hydr...
Gene Name:
UGT2B4
Uniprot ID:
P06133
Molecular Weight:
60512.035 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
other/unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Aarons L, Khan AZ, Grennan DM, Alam-Siddiqi M: The binding of flurbiprofen to plasma proteins. J Pharm Pharmacol. 1985 Sep;37(9):644-6. [PubMed:2867185 ]
  2. Takla PG, Schulman SG, Perrin JH: Measurement of flurbiprofen-human serum albumin interaction by fluorimetry. J Pharm Biomed Anal. 1985;3(1):41-50. [PubMed:16867708 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954 ]
  2. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23